Archives
-
LY2886721: Dose-Resolved BACE1 Research Guide
2026-09-16
LY2886721 is a potent BACE inhibitor for investigating amyloid precursor protein processing and amyloid beta reduction. This guide connects its biochemical, cellular, and animal-model data with assay decisions that help distinguish target engagement from synaptic or pathway-level effects.
-
Cell Counting Kit-8 (CCK-8) Plus: Practical Guide
2026-09-16
Cell Counting Kit-8 (CCK-8) Plus (SKU K2268) provides a water-soluble WST-8 readout for estimating viable-cell signal in proliferation, cytotoxicity, and drug-response experiments. This guide addresses plate setup, controls, storage, and troubleshooting when no directly matched paper evidence is available. Use it as a metabolic viability endpoint, not as a stand-alone measure of cell number, death mechanism, or compound selectivity.
-
Machine Learning for Microglia-Targeted mRNA LNPs
2026-09-15
Rafiei, Shojaei, and Chau developed a machine learning workflow to identify lipid nanoparticle designs that deliver mRNA to inflammatory microglia and alter their phenotype. The study shows that combining LNP composition, hyaluronic acid modification, morphometric analysis, and supervised learning can guide IL10 mRNA delivery, while also revealing limits in predicting responses across distinct microglial activation states.
-
TPCA-1 for Reliable NF-κB Assays
2026-09-15
Learn how TPCA-1 (SKU A4602) can help researchers distinguish NF-κB-driven inflammatory effects from nonspecific cytotoxicity in cell-based assays. This scenario-led guide covers mechanism, assay compatibility, solution preparation, data interpretation, and practical product-selection criteria.
-
Auranofin in HCC: A Redox Assay Strategy
2026-09-14
Auranofin offers a practical way to interrogate thioredoxin reductase dependence alongside the FOXO3–YAP metabolic program in hepatocellular carcinoma. This article translates recent HCC findings into a decision framework for redox, viability, apoptosis, and radiosensitization assays while distinguishing evidence from hypothesis.
-
Recombinant Human FGF-19: Assay Design Guide
2026-09-14
This scenario-based guide explains how Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized), SKU P1050, can support reproducible FGFR4 binding, proliferation, viability, and exploratory metabolic-signaling studies. It combines product specifications with practical controls and clear limits when extending FGF-19 experiments into renal inflammatory models.
-
Synthetic Lethality in Glioblastoma: Mcl-1 and BCL-XL
2026-09-13
The reference study identifies a super-enhancer controlling Mcl-1 expression in glioblastoma and shows that its epigenetic disruption can cooperate with BCL-2/BCL-XL inhibition to overcome apoptotic resistance. Across cellular and patient-derived xenograft models, the combination produced mitochondrial dysfunction, caspase activation, and reduced tumor growth, supporting a mechanistically defined strategy for preclinical GBM research.
-
JSH-23: A Mechanistic Guide to NF-κB Assays
2026-09-12
JSH-23 is an NF-κB inhibitor that can separate p65-dependent transcription from upstream IκB degradation and downstream inflammasome maturation. This guide translates PRV infection findings into practical assay decisions for inflammation research and disease modeling.
-
DAPI Nuclear Stain Solution: Practical Protocol
2026-09-11
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution is a ready-to-use fluorescent DNA binding dye for nuclear visualization and endpoint assessment of membrane-compromised cells. It is best suited to fixed, dead, or apoptotic samples analyzed by fluorescence microscopy or flow cytometry, rather than routine imaging of intact live cells.
-
Machine-Learning LNPs for Microglial Repolarization
2026-09-11
Rafiei, Shojaei, and Chau combined a 216-formulation lipid nanoparticle screen with supervised machine learning to predict mRNA transfection and microglial phenotypic responses. Their best formulation, HA-LNP2, delivered IL10 mRNA and reduced inflammatory features in activated murine and human iPSC-derived microglia, supporting a cell-state-aware approach to neuroinflammatory drug delivery.
-
Itraconazole for Candida Biofilm Workflows
2026-09-10
Build a more informative Candida workflow by pairing Itraconazole susceptibility testing with biofilm, autophagy, and oxidative-stress readouts. Its distinct value extends to CYP3A4 drug interaction studies and carefully separated hedgehog signaling or angiogenesis inhibition assays.
-
Carrier-Free Paclitaxel Nanoparticles for TNBC
2026-09-10
A 2024 ACS Applied Nano Materials study developed PTX/GA@FA-HSA, a high-drug-loading formulation in which paclitaxel and gambogic acid coassemble into a drug-rich core coated with folate-functionalized albumin. In MDA-MB-231 cell and tumor-bearing mouse models, the formulation improved folate receptor-associated delivery while reducing the need for conventional carrier material.
-
Faropenem sodium: Research Workflows and AMR Insights
2026-09-09
Faropenem sodium combines penem-class cell-wall activity with strong anaerobic coverage, making it useful for comparative susceptibility assays and resistance-focused workflows. This guide translates its reported performance into practical experimental design, controls, and troubleshooting while emphasizing responsible interpretation of oral penem data.
-
T7 RNA Polymerase for Precise RNA Synthesis
2026-09-09
T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively produces RNA from DNA templates carrying a T7 promoter. Its defined template requirements support in vitro transcription workflows for research applications such as RNA vaccine production, antisense RNA, and RNAi studies.
-
WM-8014 KAT6A Inhibitor Workflow Guide
2026-09-08
WM-8014 combines reversible, competitive KAT6A/B inhibition with practical assays for cell-cycle arrest, senescence, and oncogenic overproliferation. This guide connects RESTRICT-seq findings to dose-response, washout, transcriptional, and in vivo-compatible workflows while emphasizing solvent, timing, and interpretation controls.